NO960256L - Ekspresjon, rensing og refolding av Neisseria Meningitidis ytre membran gruppe B protein proteiner - Google Patents

Ekspresjon, rensing og refolding av Neisseria Meningitidis ytre membran gruppe B protein proteiner

Info

Publication number
NO960256L
NO960256L NO960256A NO960256A NO960256L NO 960256 L NO960256 L NO 960256L NO 960256 A NO960256 A NO 960256A NO 960256 A NO960256 A NO 960256A NO 960256 L NO960256 L NO 960256L
Authority
NO
Norway
Prior art keywords
refolding
purification
expression
outer membrane
neisseria meningitidis
Prior art date
Application number
NO960256A
Other languages
English (en)
Norwegian (no)
Other versions
NO960256D0 (no
Inventor
Milan S Blake
Joseph Y Tai
Huilin L Qi
Shu-Mei Liang
Lucjan J Hronowski
Jeffrey K Pullen
Original Assignee
Univ Rockefeller
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller, North American Vaccine Inc filed Critical Univ Rockefeller
Publication of NO960256D0 publication Critical patent/NO960256D0/no
Publication of NO960256L publication Critical patent/NO960256L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
NO960256A 1993-07-23 1996-01-22 Ekspresjon, rensing og refolding av Neisseria Meningitidis ytre membran gruppe B protein proteiner NO960256L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/096,182 US5439808A (en) 1993-07-23 1993-07-23 Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
PCT/US1994/008327 WO1995003413A1 (fr) 1993-07-23 1994-07-22 Expression a haut niveau, purification et repliement des proteines porines du groupe b de membrane externe de neisseria meningitidis

Publications (2)

Publication Number Publication Date
NO960256D0 NO960256D0 (no) 1996-01-22
NO960256L true NO960256L (no) 1996-03-20

Family

ID=22256136

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960256A NO960256L (no) 1993-07-23 1996-01-22 Ekspresjon, rensing og refolding av Neisseria Meningitidis ytre membran gruppe B protein proteiner

Country Status (12)

Country Link
US (3) US5439808A (fr)
EP (1) EP0713530A4 (fr)
JP (1) JPH09500538A (fr)
AU (1) AU690570B2 (fr)
BR (1) BR9407092A (fr)
CA (1) CA2167677A1 (fr)
FI (1) FI960309A7 (fr)
NO (1) NO960256L (fr)
NZ (1) NZ269996A (fr)
PL (1) PL182573B1 (fr)
RU (1) RU2181378C2 (fr)
WO (1) WO1995003413A1 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
EP0749321B1 (fr) * 1994-02-09 2007-01-24 Epitopix LLC Immunisation active au moyen d'un recepteur proteique de siderophore
EP0817647A4 (fr) * 1995-03-24 2002-10-30 Promega Corp Traitement contre escherichia coli producteur de verotoxines
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
PL328096A1 (en) * 1996-02-01 1999-01-04 North American Vaccine Expression of external membrane (mb3) protein of neisseria meningitidis of b group in yeasts and vaccines
GB9614700D0 (en) 1996-07-12 1996-09-04 Medical Res Council Over-expression of proteins in E.Coli
US6030810A (en) * 1997-02-26 2000-02-29 Delgado; Stephen Gregory Cloned tetrodotoxin-sensitive sodium channel α-subunit and a splice variant thereof
CA2297072A1 (fr) * 1997-07-17 1999-01-28 Baxter Healthcare S.A. Conjugues immunogenes renfermant une porine meningococcique du groupe b et un polysaccharide h. influenzae
RU2233172C2 (ru) * 1997-07-17 2004-07-27 Бакстэ Хелскеа С.А. Иммуногенный коньюгат полисахарид h. influenzae - порин менингококка группы b (варианты), способ его получения, фармацевтическая композиция и способ индукции иммунного ответа у животного в отношении h.influenzae
SE9704175D0 (sv) * 1997-11-14 1997-11-14 Alfa Laval Agri Ab An animal stall
US7335477B2 (en) * 1997-12-24 2008-02-26 The United States Of America As Represented By The Secretary Of The Navy Truncated recombinant major outer membrane protein antigen (r56) of Orientia tsutsugamushi strains Karp, Kato and Gilliam and its use in antibody based detection assays and vaccines
US7638130B2 (en) * 1997-12-24 2009-12-29 The United States Of America As Represented By The Secretary Of The Navy Truncated recombinant major outer membrane protein antigen (R56) of Orientia tsutsugamushi strains Karp, Kato and Gilliam and its use in antibody based detection assays and vaccines
US6482415B1 (en) * 1997-12-24 2002-11-19 The United States Of America As Represented By The Secretary Of The Navy Expression and refolding of truncated recombinant major outer membrane protein antigen (r56) of Orientia tsutsugamushi and its use in antibody based detection assays and vaccines
WO1999036544A2 (fr) * 1998-01-14 1999-07-22 Chiron S.P.A. Antigenes du $i(neisseria meningitidis)
US6284250B1 (en) * 1998-02-05 2001-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
EP2261347A3 (fr) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
CN1263510C (zh) * 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
US20110045011A1 (en) * 1998-12-22 2011-02-24 Wei-Mei Ching TRUNCATED RECOMBINANT MAJOR OUTER MEMBRANE PROTEIN ANTIGEN (R56) OF ORIENTIA TSUTSUGAMUSHI STRAINS KARP, KATO and GILLIAM AND ITS USE IN ANTIBODY BASED DETECTION ASSAYS AND VACCINES
US7081244B2 (en) * 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
CA2371928C (fr) 1999-02-22 2013-08-13 Microbiological Research Authority Compositions de vaccin a neisseria et procedes correspondants
CA2372235A1 (fr) 1999-04-30 2000-11-09 Rino Rappuoli Antigenes de neisseria conserves
AU783894B2 (en) 1999-05-19 2005-12-22 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
EP1234039A2 (fr) 1999-11-29 2002-08-28 Chiron Spa ANTIGENE DE NEISSERIA A 85kDa
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2871789C (fr) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Vaccin a base de vesicule de membrane externe (omv) comprenant des proteines de membrane externe du serogroupe b de n. meningitis
DK1947187T5 (da) * 2000-02-28 2011-10-24 Novartis Vaccines & Diagnostic Hybrid ekspression af neisserial-proteiner
CA2433561C (fr) * 2001-01-03 2014-04-01 Willmar Poultry Company, Inc. Compositions comportant des proteines du recepteur siderophore gram negatif et methodes pour les utiliser
WO2002083069A2 (fr) * 2001-04-13 2002-10-24 United States Of America As Represented By The Secretary Of The Navy Antigene tronque recombine majeur de proteine membranaire externe (r56) de souches karp, kato et gilliam d'orientia tsutsugamushi et son utilisation dans des dosages de detection bases sur des anticorps et des vaccins
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
CA2493124C (fr) * 2002-08-02 2014-04-29 Glaxosmithkline Biologicals S.A. Vaccin
US20040197845A1 (en) * 2002-08-30 2004-10-07 Arjang Hassibi Methods and apparatus for pathogen detection, identification and/or quantification
CN1809380B (zh) 2002-10-11 2010-05-12 启龙有限公司 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
EP1638602A1 (fr) 2003-06-23 2006-03-29 Baxter International Inc. Vaccins contre neisseria meningitidis du groupe y et combinaisons meningococciques desdits vaccins
ES2395022T3 (es) * 2003-09-19 2013-02-07 Epitopix, Llc Polipéptidos de Campylobacter y sus métodos de uso
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
LT2682126T (lt) 2005-01-27 2017-02-27 Children`s Hospital & Research Center at Oakland Gna1870 pagrindu gaminamos pūslelių pavidalo vakcinos, skirtos plataus spektro apsaugai nuo neisseria meningitidis sukeltų ligų
CA2753814C (fr) 2009-02-27 2018-07-31 Novartis Ag Systeme de vecteurs d'expression comprenant deux marqueurs de selection
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX357538B (es) 2012-06-14 2018-07-13 Novartis Ag Vacunas para meningococo de serogrupo x.
EP3027646B1 (fr) 2013-07-31 2018-06-27 Novartis AG Nouveaux vecteurs de sélection et procédés de sélection de cellules hôtes eucaryotes
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP4034157A1 (fr) 2019-09-27 2022-08-03 Pfizer Inc. Compositions de neisseria meningitidis et méthodes associées

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134214A (en) * 1977-08-05 1979-01-16 Merck & Co., Inc. Freeze-drying process for the preparation of meningococcus vaccine without degradation of potency
US4271147A (en) * 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
DE3070388D1 (en) * 1980-10-02 1985-05-02 Schering Corp Injectable rabies vaccine composition and method for preparing same
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4451446A (en) * 1982-03-04 1984-05-29 Smithkline-Rit Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
ES2051909T3 (es) * 1988-04-19 1994-07-01 American Cyanamid Co Vacuna del conjugado de polisacarido-proteina de membrana externa contra la haemophilus influenzae tipo b.
US5192540A (en) * 1988-04-19 1993-03-09 American Cyanamid Company Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
EP0351604B1 (fr) * 1988-06-29 1994-09-14 The Rockefeller University Vaccins contre Neisseria
EP0449958B9 (fr) * 1988-12-19 2003-05-28 American Cyanamid Company Vaccin meningocoque de la proteine de la membrane externe de la classe 1
AU5343390A (en) * 1989-03-31 1990-11-05 Immunomed Corporation Preparation of unassembled pilus subunits and vaccines containing them
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp Conjugate vaccine formed from a polysaccharide and a c protein of b-streptococcus
ATE121947T1 (de) * 1989-12-14 1995-05-15 Ca Nat Research Council Verbessertes meningokokkale polysaccharidkonjugatvakzin.
SU1761807A1 (ru) * 1990-06-27 1992-09-15 Всесоюзный научно-исследовательский институт антибиотиков Штамм бактерий ЕSснеRIснIа coLI
FI903414A7 (fi) * 1990-07-06 1992-01-07 Kansanterveyslaitos Produktion av proteiner i grampositiva bakterier.
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
DE69133276T2 (de) * 1990-07-16 2003-11-27 University Of North Carolina At Chapel Hill, Chapel Hill Mit der familie der hämolysin-toxine verwandte antigene eisen-ubnterdrückende proteine des n. meningitis
CA2047031A1 (fr) * 1990-07-19 1992-01-20 Stephen Marburg Vaccins conjugues de peptide-polysaccharide-proteine
EP0467714A1 (fr) * 1990-07-19 1992-01-22 Merck & Co. Inc. Classe II de la membrane extérieure de Neisseria meningitidis et raccins la contenant
JP3532563B2 (ja) * 1990-08-23 2004-05-31 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル Ｎｅｉｓｓｅｒｉａ ｇｏｎｏｒｒｈｏｅａｅおよびＮｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ由来トランスフェリン結合蛋白質
CA2057536C (fr) 1990-12-21 1999-10-26 John J. Dunn Clonage et expression des lipoproteines de borrelia
CA2059692C (fr) * 1991-01-28 2004-11-16 Peter J. Kniskern Vaccin conjugue de polysaccharide contre les pneumocoques
CA2105965A1 (fr) * 1991-03-15 1992-09-16 Nelson Teng Conjugues de vehicules immunogenes/analogues de lipides a; leur emploi comme vaccins et gammaglobulines hyperimmunes polyvalentes
CA2071088A1 (fr) * 1991-06-19 1992-12-20 Emilio A. Emini Conjugues de la proteine de classe ii de la membrane externe de neisseria meningitidis et de peptides relies au vih-1, et vaccins en contenant
US5425946A (en) * 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis

Also Published As

Publication number Publication date
CA2167677A1 (fr) 1995-02-02
JPH09500538A (ja) 1997-01-21
AU7371694A (en) 1995-02-20
US5879686A (en) 1999-03-09
US5439808A (en) 1995-08-08
PL182573B1 (pl) 2002-01-31
AU690570B2 (en) 1998-04-30
FI960309A0 (fi) 1996-01-23
WO1995003413A1 (fr) 1995-02-02
BR9407092A (pt) 1996-09-03
FI960309L (fi) 1996-03-22
FI960309A7 (fi) 1996-03-22
EP0713530A4 (fr) 2002-09-18
EP0713530A1 (fr) 1996-05-29
NZ269996A (en) 1997-10-24
NO960256D0 (no) 1996-01-22
PL312712A1 (en) 1996-05-13
US6013267A (en) 2000-01-11
RU2181378C2 (ru) 2002-04-20

Similar Documents

Publication Publication Date Title
NO960256D0 (no) Ekspresjon, rensing og refolding av Neisseria Meningitidis ytre membran gruppe B protein proteiner
NO983474D0 (no) Ekspresjon av gruppe B Neisseria meningsitidis yttermembran-protein (MB3) fra gjµr og vaksiner
DK0539530T3 (da) Rensningsstyret kloning af peptider
ATE244016T1 (de) Protein der ausseren membran von moraxella catarrhalis omp-106, dessen gensequenz und dessen verwendung
DE69623116D1 (de) Gasdurchlässiges membran
DK470489D0 (da) Fremgangsmaade til oprensning og foldning af rekombinante proteiner
IS4345A (is) Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur
AU657487B2 (en) Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations
NO972214L (no) Fremgangsmåte for rensing og isolering av 2'-deoksy-2',2'-difluornukleosider
DE69333802T8 (de) Äusseres membranprotein von haemophilus
DK57391A (da) Hiv proteiner og peptider til anvendelse ved diagnosticering, profylakse og behandling af aids
ES2156602T3 (es) Expresion de albumina en levaduras.
NO893549L (no) Semipermeabel membran av komposittmateriale og fremgangsmaate til fremstilling derav.
HUP9802349A2 (hu) Allergén - XCD32 fúziós fehérjék és eljárás allergiaellenes gyógyszerkészítmény előállítására
DK441386A (da) Understoettet membran og fremgangsmaade til fremstilling deraf
NO960255D0 (no) Fremgangsmåte for ekspresjon og rensing av P2 protein fra haemophilus influenzae type B
DK278289D0 (da) Ekspressionsvektorer, deres fremstilling og anvendelse til fremstilling af ufusionerede proteiner i mikroorganismer
DK614086D0 (da) Sammensat semipermeabel membran og fremstilling deraf
NO991227L (no) PTX-sensitive G-proteiner, deres fremstilling og bruk
NO982734L (no) FremgangsmÕte for rensing av rekombinant humaninterleukin-8
AU7614798A (en) High level expression, purification and refolding of the Neisseria meningitidis outer membrane group B porin proteins
DE69204136D1 (de) Membran und Trennverfahren.
NO874163D0 (no) Fremgangsmaate for rensing av rekombinante proteiner og produkter derav.
DK0845040T3 (da) Plastidindre kappemembranmålretningspolypeptider; fremstilling og anvendelse deraf

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application